ABSTRACT A large set of Bacillus megaterium CYP102A1 mutants are known to metabolize various drugs to form human metabolites. Omeprazole (OMP), a proton pump inhibitor, has been widely used as an acid inhibitory agent for the treatment of gastric acid hypersecretion disorders. It is primarily metabolized by human CYP2C19 and CYP3A4 to 59-OH OMP and a sulfone product, respectively. It was recently reported that several CYP102A1 mutants can oxidize racemic and S-OMP to 59-OH OMP and that these mutants can further oxidize 59-OH racemic OMP to 59-COOH OMP. Here, we report that the S-and R-enantiomers of OMP are hydroxylated by 26 mutants of CYP102A1 to produce 1 major metabolite (59-OH OMP) regardless of the chirality of the parent substrates. Although the binding of R-OMP to the CYP102A1 active site caused a more apparent change of heme environment compared with binding of S-OMP, there was no correlation between the spectral change upon substrate binding and catalytic activity of either enantiomer. The 59-OH OMP produced from racemic, S-, and R-OMP could be obtained with a high conversion rate and high selectivity when the triple R47L/F87V/L188Q mutant was used. These results suggest that bacterial CYP102A1 mutants can be used to produce the human metabolite 59-OH OMP from both the S-and R-enantiomers of OMP.
Introduction
Omeprazole (OMP), a proton pump inhibitor (PPI), acts to regulate acid production in the stomach by irreversible binding to the proton pump (H + -K + ) ATPase in the gastric parietal cell. It is used for the treatment of gastric acid hypersecretion disorders including dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome. It is administered as a racemic mixture of the R-and S-enantiomers. OMP is primarily metabolized by the hepatic enzymes CYP2C19 and CYP3A4. Both CYP2C19 and CYP3A4 exhibit a stereoselective metabolism of OMP. CYP2C19 favors 59-hydroxylation of R-OMP, whereas sulfoxidation mediated by CYP3A4 highly favors the S-form (Yamazaki et al., 1997; Abelö et al., 2000; Li et al., 2005) (Fig. 1) . S-OMP (esomeprazole; Nexium) has been developed as a new drug with the goal of improving the pharmacokinetic and pharmacodynamic profiles of racemic omeprazole (McKeage et al., 2008) . It is known that esomeprazole is significantly more active against Helicobacter pylori than omeprazole. Esomeprazole was not associated with either gastric dysplasia or neoplasia after long-term treatment in patients with healed reflux esophagitis.
CYP2C19 is a highly polymorphic enzyme, with variations in both mRNA and protein expression as well as differences in the protein coding region, which give rise to differing rates of catalysis (Goldstein, 2001) . The proportion of the poor metabolizer phenotype varies widely between populations, from approximately 2% for Caucasians to nearly approximately 20% in Asians. Several pharmacogenomic studies have suggested that PPI treatment should be tailored according to the patient's CYP2C19 metabolism status (Furuta et al., 2005) . A large set of CYP2C19 alleles from ethnically different populations has been reported (http://www. cypalleles.ki.se/cyp2c19.htm). The PPI omeprazole and related ulcer drugs are primarily oxidized by CYP2C19, and poor metabolizers show a better response to these drugs (Kawabata et al., 2003) .
The importance of drug metabolites has been recognized in several International Conference on Harmonisation (ICH) safety guidelines such as the ICH S7A, ICH S3A, and ICH M3 (http://www.ich.org/ products/guidelines/safety/article/safety-guidelines.html; Atrakchi, 2009) . Some drug metabolites of concern can be prepared by chemical methods, but others are generally prepared by several enzyme sources, including recombinant human P450 enzymes (Yun et al., 2006) . Some bacterial P450s are already known to be competitive biocatalysts for metabolite production due to their high activities and stabilities (Julsing et al., 2008; Whitehouse et al., 2012; Kang et al., 2014) . Currently, a large set of CYP102A1 mutants are known to have similar activities to human P450 as well as the ability to metabolize a number of marketed drugs and steroids (Yun et al., 2007; Whitehouse et al., 2012; Kang et al., 2014) . Therefore, CYP102A1 is generally accepted as a prototype monooxygenase for the development of versatile biocatalysts for use in drug discovery and synthesis (Urlacher and Girhard, 2012; Kang et al., 2014) . Recently, the 59-hydroxylation activity of CYP102A1 mutants on racemic OMP (Butler et al., 2013; Yun et al., 2013) and S-OMP (Butler et al., 2014) has been reported. It was also shown that 59-OH racemic OMP can be further oxidized to a carboxylated product (Butler et al., 2013) .
The aim of this study was to investigate the enzymatic properties of CYP102A1 mutants to generate the 59-OH product from S-and R-OMP enantiomers. It was found that a set of CYP102A1 mutants could catalyze the formation of 59-OH OMP regardless of the chirality of the substrate. Although human CYP2C19 and CYP3A4 form 59-OH and sulfone products, respectively, CYP102A1 mutants could produce 59-OH OMP (but not other products) as the major metabolite. Some of the CYP102A1 mutants tested here were able to catalyze the oxidation of OMP to generate its primary metabolite, 59-OH OMP, from S-and R-enantiomers with a high conversion rate and high selectivity.
Materials and Methods
Chemicals. OMP (racemic mixture), S-OMP, and NADPH were purchased from Sigma-Aldrich (St. Louis, MO). R-OMP was obtained from Santa Cruz Biotechnology (Dallas, TX). Other chemicals were of the highest grade commercially available.
Construction of CYP102A1 Mutants by Site-Directed Mutagenesis and Random Mutagenesis. Wild-type and 26 different mutants of CYP102A1 used in this study were prepared as previously described (Kim et al., 2008; Park et al., 2010) . The mutants were selected based on their activities toward a variety of human P450 substrates and drugs. Mutants 1-17 have mutations in the substrate channel and active site (Kim et al., 2008) , and mutants 18-26 have mutations outside of the active site and substrate channel (Park et al., 2010) . Each mutant bears amino acid substitution(s) relative to wild-type CYP102A1, as summarized in Supplemental Table 1 .
Expression and Purification of Wild-Type and Mutant Enzymes of CYP102A1. Wild-type and 26 mutants of CYP102A1 were expressed in the Escherichia coli strain DH5aF9-IQ and purified as previously described (Kim et al., 2008; Park et al., 2010) . The CYP102A1 concentrations were determined by CO difference spectra using « = 91 mM 21 /cm
21
. For all of the wild-type and mutated enzymes, a typical culture yielded 200-700 nM P450.
Hydroxylation of OMP. Typical steady-state reactions for the hydroxylation of each OMP enantiomer included 50 pmol CYP102A1 in 0.25 ml of 100 mM potassium phosphate buffer (pH 7.4) containing a final concentration of 100 mM OMP (racemic mixture, S-enantiomer, or R-enantiomer). To determine the kinetic parameters of several CYP102A1 mutants, a range of concentrations of OMP (2-1000 mM) was used. An aliquot of a NADPH-generating system was used to initiate reactions (final concentrations: 10 mM glucose 6-phosphate, 0.5 mM NADP+, and 1 IU/ml yeast glucose 6-phosphate dehydrogenase). A stock solution of OMP (200 mM) was prepared in dimethyl sulfoxide and diluted into the enzyme reactions with a final organic solvent concentration of ,1% (v/v). OMP is soluble at the diluted solution of 2 mM concentration [1% (v/v)].
Reactions were incubated for 30 minutes at 37°C and terminated with 0.50 ml ice-cold dichloromethane. After centrifugation of the reaction mixture, organic phases were evaporated under nitrogen gas. The product was analyzed by highperformance liquid chromatography (HPLC) using a Gemini C18 column (4.6 Â 150 mm, 5 mm; Phenomenex, Torrance, CA) with an acetonitrile/water [30:70 (v/v)] mobile phase. Elutes were detected by UV light at 302 nm. Phenacetin was used as an internal standard as previously described (Kobayashi et al., 1994) . The kinetic parameters (k cat and K m ) were determined using nonlinear regression analysis based on the Michaelis-Menten kinetics model with GraphPad Prism software (GraphPad Software Inc., San Diego, CA).
To determine the total turnover numbers (TTNs) of each CYP102A1 mutant, 1.0 mM OMP (racemic mixture, S-enantiomer, or R-enantiomer) and 200 pmol enzyme were used in 0.50 ml of 100 mM potassium phosphate buffer (pH 7.4). The reaction was initiated by the addition of the NADPH-generating system and incubated for 10 minutes to 4 hours at 37°C. The formation rate of the OMP metabolite was determined by HPLC as described above.
Isolation of 59-OH OMP. To prepare the metabolites of racemic and S-OMP, we used a scale of 20-ml reaction volume in 20 test tubes (each 1 ml, under air). Each reaction mixture contained 400 pmol of CYP102A1 mutant 10, a NADPH-generating system, and 1 mM racemic OMP or S-OMP in 1 ml of 100 mM potassium phosphate buffer (pH 7.4). Reaction was initiated by the addition of the NADPH-generating system and was incubated for 2 hours at 37°C. The reaction was terminated with two volumes of ice-cold dichloromethane. After centrifugation of the reaction mixture, organic phases from 20 test tubes were combined and evaporated under nitrogen gas. The chromatographic separation was achieved using a semi-preparative Gemini C18 column (10 Â 250 mm, 10 mm particle size; Phenomenex) monitored at A 302 . The mobile phase was 30% acetonitrile and was delivered at a flow rate of 3.0 ml/min. Retention times for 59-OH metabolite and OMP were 8.75 min 21 and 21.01 min 21 , respectively. After collection of the 59-OH metabolite fraction and drying under nitrogen gas, the dried metabolite was obtained and used for nuclear magnetic resonance (NMR) analysis. The 59-OH OMP was also used an authentic standard. For typical reaction, about 3.0 mg of the 59-OH OMP was obtained from the 20-ml reaction.
Liquid Chromatography-Mass Spectrometry Analysis. To identify the metabolite of each OMP enantiomer produced by the CYP102A1 mutants, liquid chromatography-mass spectrometry (LC-MS) analysis was carried out. The oxidation reaction of OMP by CYP102A1 mutants was performed as described above. For the activity assays of human CYP2C19 and CYP3A4, a control experiment of 50 pmol P450, 100 pmol rat NADPH-P450 reductase, and 50 mM L-a-dilauroyl-sn-glycero-3-phosphocholine was performed in 0.25 ml of 100 mM potassium phosphate buffer (pH 7.4). After extraction and Fig. 1 . Structures of the OMP enantiomers and their respective metabolites. R-OMP is primarily metabolized by CYP2C19 for 59-OH R-OMP. S-OMP is mainly metabolized by CYP3A4 for 5-O-desmethyl OMP and OMP sulfone, which is further hydroxylated by CYP2C19. In this study, we observed that both enantiomers are hydroxylated by CYP102A1 mutants.
centrifugation, organic phases were evaporated under nitrogen gas. An aliquot (5 ml) of the reconstituted residue was injected onto the liquid chromatography column. LC-MS analysis was performed on a Shimadzu LCMS-2010 EV system (Shimadzu, Kyoto, Japan) including LC-MS solution software. The separation was performed on a Shim-pack VP-ODS column (2.0 Â 250 mm; Shimadzu) with a mobile phase of CH 3 CN/H 2 O [70:30 (v/v) ] at a flow rate of 0.10 ml/min. To identify the metabolites, mass spectra were recorded by electrospray ionization in positive mode. The interface and detector voltages were 4.4 and 1.5 kV, respectively. The nebulization gas flow was set at 1.5 l/min. The interface, curve desolvation line, and heat block temperatures were 250°C, 230°C, and 200°C, respectively.
Identification of OMP Metabolites by NMR Spectroscopy. NMR experiments were performed on a Varian VNMRS 600 MHz NMR spectrometer equipped with a carbon-enhanced cryogenic probe (Korea Basic Science Institute, Gwangju, Korea). Acetone-d 6 was used as a solvent, and chemical shifts for the proton NMR spectrum were measured in parts per million relative to the tetramethylsilane. All of the NMR experiments were performed with standard pulse sequences in the VNMRJ (v. 2.3) library and were processed with the same software. There have been reports on proton and carbon chemical shifts of racemic omeprazole in acetone-d 6 . Spectral assignments of racemic 59-OH OMP were carried out mainly with a one-dimensional proton NMR spectrum of 59-OH OMP by comparing with reported chemical shift values of racemic omeprazole (Folli et al., 1995; Yang et al., 2003) . Redondo et al. (2010) showed that it is possible to differentiate chiral isomers of omeprazole in nonpolar NMR solvents by adding (S)-1,10-binaphthyl-2,20-diol as an NMR chiral solvating agent.
Spectral Binding Titrations. Spectral binding titrations were used to determine the dissociation constants (K s ) for substrates as previously described (Kim et al., 2008) . The binding affinities of the ligands to the CYP102A1 enzymes were determined at 23°C by titrating 1.5 mM enzyme with the ligand in a total volume of 1.0 ml of 100 mM potassium phosphate buffer (pH 7.4). The final dimethyl sulfoxide concentration was ,2% (v/v). The spectral dissociation constants (K s ) were estimated using GraphPad Prism software.
Results and Discussion
Hydroxylation of OMP Enantiomers by Wild-Type CYP102A1 and Its Mutants. Initially, the catalytic activity of wild-type and various CYP102A1 mutants toward S-and R-OMP was investigated at a fixed substrate concentration of 100 mM (Fig. 2) . The wild-type and mutant enzymes produced only one major metabolite (59-OH OMP) for both enantiomers. The 59-OH product formation rates for the mutants for R-OMP were much higher than those for S-OMP (Figs. 2  and 3 ). The turnover numbers from the 26 mutants for 59-OH OMP formation varied over a wide range. The wild-type enzyme as well as mutants 2, 4, 5, 12, 14, and 15 showed lower catalytic activity for both enantiomers (,1.0 min 21 ). Although 13 mutants showed high catalytic activity (.10 min
21
) for R-OMP, only 4 mutants exhibited catalytic activity .10 min 21 for S-OMP. The turnover numbers for mutants 10, 17, and 21 were 140-to 220-fold and 90-to 140-fold higher than those of the wild-type enzyme for S-OMP (0.16 min
) and R-OMP (0.37 min 21 ), respectively. The metabolites were identified by HPLC, LC-MS, and NMR. The retention time and fragmentation pattern of the major OMP metabolite from both S-and R-OMP were matched to the 59-OH OMP standard (Supplemental Figs. 1 and 2 ). Mutants 10, 13, 16, 21, and 22 were selected for additional kinetic analysis and binding studies.
When we compared the S-OMP 59-hydroxylation activity with R-OMP 59-hydroxylation activity in the 26 mutants, several statistically significant correlations (r = 0.97, P , 0.0001) were observed (Supplemental Fig. 3 ). This result indicates that chirality of the sulfur center is not critical for the hydroxylation reaction at the 59-C position. Taken together, this suggests that the CYP102A1 mutants can be used to prepare the 59-OH OMP product regardless of the chirality of the parent substrates.
Structural Characterization of the Major Metabolite 59-OH S-OMP Generated by CYP102A1. Mutant 10 was used to prepare the 59-OH OMP from S-OMP for structural analysis by NMR and LC-MS. Racemic 59-OH OMP (Supplemental Fig. 4A ), a metabolite from racemic omeprazole (Supplemental Fig. 4B ), was first identified by comparing with reported chemical shift values of racemic omeprazole (Folli et al., 1995; Yang et al., 2003) . No structural change in benzoimidazole moiety is evident in 1 H spectra of the racemic OMP and racemic 59-OH OMP, whereas chemical shift changes in the pyridine moiety with conversion of 59-CH 3 (d 2.245 ppm) in racemic OMP to 59-CH 2 OH (d 4.698 ppm) in racemic 59-OH OMP can be seen in the 1 H spectrum of racemic 59-OH OMP (Supplemental Fig. 5 ). Table 2 ). The position of racemic 59-hydroxymethyl group was further confirmed with one-dimensional selective rotating frame nuclear Overhauser effect experiments. When already-assigned proton NMR peaks from H-69 (d 8.41 ppm) or 49-OCH 3 (d 3.81 ppm) were selectively irradiated, proton NMR peak from 59-CH 2 (d 4.70 ppm) appeared (Supplemental Fig. 6 ). The key rotating frame nuclear Overhauser effect results are shown in Supplemental Fig. 4C . The proton NMR spectrum of the metabolite from S-OMP, was identical to that of the metabolite from racemic 59-OH OMP as we expected (Supplemental Fig. 7) .
Kinetic Parameters and TTNs of OMP 59-Hydroxylation by CYP102A1 Mutants. Five mutants were selected to compare the kinetic parameters for the 59-hydroxylation of S-and R-OMP (Supplemental Fig. 8 ; Supplemental Table 3 ). Although the k cat values of each mutant were similar among the racemate, S-OMP, and R-OMP, the K m values were in the wide range for all tested mutants. Mutants 10 (R47L/ F87V/L188Q mutant) and 22 (F162I/E228K) showed high k cat values (47-122 min
) for the three OMP substrates. The results indicate that the mutants did not show any preference toward a specific enantiomer. The mutant 10 was used to measure the TTN (mol product/mol catalyst) for the 59-hydroxylation reaction of S-and R-OMP (Supplemental Fig.  9 ). The overall values were 950 and 1200 for 59-OH product from S-and R-OMP, respectively, when 1 mM of substrate was used.
Selective Conversion of OMP to 59-OH OMP. Of the 26 mutants of CYP102A1 that reacted with 1 mM of OMP for 1 hour, mutant 10 possessed the most ideal combination of 59-OH OMP formation dmd.aspetjournals.org activity and regioselectivity. Mutant 10 produced 59-OH OMP at 93%, 98%, and 88% selectivity with the racemic, S-, and R-OMP, respectively ( Fig. 2 ; Supplemental Table 4 ). It also converted up to 97%, 99%, and 100% of the racemic, S-, and R-OMP into 59-OH OMP, respectively. This result indicates that 59-OH OMP can be obtained with a high conversion rate and high selectivity from racemic, S-, and R-OMP.
Binding of OMP to CYP102A1 Mutants. Ferric CYP102A1 exhibits a low-spin state, and the addition of substrate (OMP) produced a conversion rate in the spin state depending on the different types of CYP102A1 mutant (Butler et al., 2013) . Mutants 10, 13, 16, 22, and 23 (which were the same enzymes used to determine the kinetic parameters) were used for the binding titration. Among the 18 samples tested here for spectral titration, only 5 samples showed typical conversion (type I) from the low-spin to high-spin state, with an increase in absorbance at 390 nm and a decrease in absorbance at 420 nm (Supplemental Fig. 10 ). The binding affinities of mutants 10 and 16 to racemic OMP were determined (K s = 109 6 5 mM and 209 6 26 mM, respectively). The binding affinities of mutants 10, 13, and 16 to R-OMP were also determined (K s = 64 6 5 mM, 10 6 2 mM, and 48 6 2 mM, respectively). Six of the samples did not show apparent conversion. Although seven samples showed a spectral change, the K s value could be not obtained based on the spectral change.
Binding titration showed that there were no correlations between the spectral change upon substrate binding and catalytic activity. In the cases of mutants showing typical spectral conversion upon OMP binding, the binding affinities of the CYP102A1 mutants tested here were much lower than that of the CYP102A1 F87A/A82F mutant (K s = 0.212 mM) (Butler at al., 2013) .
Mutants 21 (F162I/K187E) and 22 (F162I/E228K) showed different spectral changes from other mutants that had mutations in the substrate channel and active site. The mutations (F162 and E228) outside of active site and substrate channel appear to have different effects on the conformation of the active site upon binding to the substrates (Supplemental Fig. 11 ).
It has been reported that 59-OH OMP was a superior agent for gastric acid hypersecretion disorders with fewer severe adverse effects, reduced potential for drug-drug interactions, and a more predictable dosing regimen compared with OMP (Yelle and Handley, 2001). However, there are no reports to show that 59-OH OMP is an active metabolite. Although the racemate of 59-OH OMP could be obtained by chemical synthesis, this synthesis includes 21 steps (Renberg et al., 1989) . The individual enantiomers from the racemate could be separated by additional oxidation and reduction steps (Yelle and Handley, 2001) .
It is now possible to study the effects of 59-OH OMP of each enantiomer on gastric acid hypersecretion disorders in in vitro, in vivo, and animal model systems because scalable production of the metabolite is possible. Specifically, the effects of the 59-OH metabolites from racemic, S-, and R-OMP on several diseases caused by gastric acid hypersecretion are of particular interest. The effects of these metabolites on gastric acid hypersecretion disorders may suggest that the metabolites could be used as "drug leads" to avoid interindividual variations in drug metabolizing enzymes and drug-drug interactions. Furthermore, the metabolites can be used as leads and subjected to further structural modifications to obtain improved clinical candidates during the lead optimization phase of the drug discovery process.
In summary, we report that the S-and R-enantiomers of OMP are hydroxylated by a set of 26 CYP102A1 mutants to produce the major metabolite 59-OH OMP regardless of the chirality of the parent substrates. The 59-OH product formation rates of the mutants for R-OMP were much higher than those for S-OMP. There were no differences for regioselectivity of the oxidation reaction for both enantiomers. Although the binding of R-OMP to the CYP102A1 active site causes a more obvious change of the heme environment than that of S-OMP, there were no correlations between the spectral change upon substrate Fig. 3 . Conversion of racemic, R-, and S-OMP to 59-hydroxylated metabolites by CYP102A1 mutant 10. Assays were performed for 1 hour using 1 mM of each substrate. HPLC chromatograms of racemic OMP (A), S-OMP (C), and R-OMP (E) and their corresponding 59-OH metabolites (B, D, and F, respectively) produced by CYP102A1 mutant 10. The peaks of the substrate and 59-OH product are indicated. The UV absorbance was monitored at 302 nm.
binding and catalytic activity. The 59-OH OMP of racemic, S-, and R-OMP could be obtained with a high conversion rate and high selectivity when the triple R47L/F87V/L188Q mutant was used. These results show that the 59-OH OMP of each enantiomer could be obtained using a one-step reaction with the CYP102A1 mutants with a high yield. Wrote or contributed to the writing of the manuscript: Ryu, K.D. Park, Yun.
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